BioMarin Pharmaceutical Inc. $BMRN Shares Newly Acquired by First Financial Bank Trust Division

Key Points

• First Financial Bank Trust Division acquired 32,420 BioMarin shares worth approximately $1.95 million in the third quarter. Institutional investors collectively own 98.71% of BMRN’s outstanding stock.
• Analysts maintain a generally positive outlook, with BioMarin receiving a “Moderate Buy” consensus rating and an average price target of $89.17, despite differing individual targets and ratings.
• BioMarin reported quarterly earnings of $1.20 per share, exceeding estimates of $0.95, while revenue rose 20% year over year to $989.71 million. Shares recently traded at $58.44, below the 52-week high of $70.98.

First Financial Bank Trust Division acquired a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 32,420 shares of the biotechnology company's stock, valued at approximately $1,945,000.

A number of other hedge funds have also modified their holdings of the company. Parkside Financial Bank & Trust lifted its stake in BioMarin Pharmaceutical by 70.3% in the 2nd quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company's stock valued at $26,000 after acquiring an additional 187 shares in the last quarter. Caerus Investment Advisors LLC boosted its position in BioMarin Pharmaceutical by 2.8% during the 4th quarter. Caerus Investment Advisors LLC now owns 10,236 shares of the biotechnology company's stock worth $608,000 after acquiring an additional 278 shares during the last quarter. Chicago Partners Investment Group LLC grew its stake in shares of BioMarin Pharmaceutical by 2.4% during the 1st quarter. Chicago Partners Investment Group LLC now owns 12,183 shares of the biotechnology company's stock worth $660,000 after acquiring an additional 290 shares in the last quarter. 4WEALTH Advisors Inc. grew its stake in shares of BioMarin Pharmaceutical by 8.8% during the 1st quarter. 4WEALTH Advisors Inc. now owns 3,880 shares of the biotechnology company's stock worth $213,000 after acquiring an additional 313 shares in the last quarter. Finally, Parallel Advisors LLC raised its holdings in shares of BioMarin Pharmaceutical by 33.9% in the first quarter. Parallel Advisors LLC now owns 1,768 shares of the biotechnology company's stock valued at $100,000 after purchasing an additional 448 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

BMRN has been the topic of a number of research reports. Royal Bank Of Canada cut their price objective on shares of BioMarin Pharmaceutical from $66.00 to $62.00 and set a "sector perform" rating on the stock in a research report on Tuesday, July 7th. Oppenheimer raised their target price on shares of BioMarin Pharmaceutical from $95.00 to $97.00 and gave the company an "outperform" rating in a research report on Friday, August 7th. Piper Sandler lifted their price target on shares of BioMarin Pharmaceutical from $88.00 to $90.00 and gave the company an "overweight" rating in a research note on Tuesday, September 1st. Barclays boosted their price target on shares of BioMarin Pharmaceutical from $105.00 to $111.00 and gave the stock an "overweight" rating in a research report on Monday, August 17th. Finally, HC Wainwright restated a "neutral" rating and set a $60.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $89.17.

BioMarin Pharmaceutical Stock Performance

Shares of NASDAQ BMRN traded down $1.56 during trading hours on Thursday, reaching $58.44. 2,082,177 shares of the stock were exchanged, compared to its average volume of 2,062,336. The firm has a market capitalization of $11.31 billion, a price-to-earnings ratio of 157.95, a P/E/G ratio of 0.43 and a beta of 0.24. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. BioMarin Pharmaceutical Inc. has a 52 week low of $49.26 and a 52 week high of $70.98. The stock's fifty day simple moving average is $64.18 and its 200 day simple moving average is $58.65.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The business had revenue of $989.71 million during the quarter, compared to analysts' expectations of $932.03 million. During the same period last year, the firm posted $1.44 EPS. The firm's revenue for the quarter was up 20.0% compared to the same quarter last year. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Sell-side analysts predict that BioMarin Pharmaceutical Inc. will post 4.1 EPS for the current year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company that develops and commercializes therapies for rare and serious genetic diseases. The company focuses on conditions with limited treatment options, using approaches that include enzyme replacement therapy, small-molecule medicines, biologics and gene therapy.

Its products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for CLN2 disease, Palynziq and Kuvan for phenylketonuria, and Voxzogo for children with achondroplasia and open growth plates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.